Samsung Biologics to Raise $2.2 Billion to Fund PolyPeptide Deal

Samsung Biologics announced a rights offering to raise approximately 3 trillion won, equivalent to $2.2 billion, to finance its acquisition of PolyPeptide Group. A rights offering allows existing shareholders to purchase additional shares at a set price, typically at a discount to the current market price. The company did not disclose a timeline for completing the offering or the acquisition.

Next story